Pfizer (PFE) Goodwill & Intangibles (2009 - 2026)

Pfizer (PFE) has 18 years of Goodwill & Intangibles data on file, last reported at $124.0 billion in Q1 2026.

• Quarterly Goodwill & Intangibles rose 1.26% year-over-year to $124.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.0 billion (up 1.26% YoY) and the FY2025 annual result came in at $125.0 billion, up 0.85% from the prior year.
• Goodwill & Intangibles slipped to $124.0 billion in Q1 2026 per PFE's latest filing, from $125.0 billion in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $132.7 billion in Q4 2023 and bottomed at $77.6 billion in Q4 2022.
• The 5-year median for Goodwill & Intangibles is $121.7 billion (2025), against an average of $110.0 billion.
• The widest annual swing landed in 2024, when Goodwill & Intangibles soared 41.34%; it then decreased 7.35% in 2025.
• Tracing PFE's Goodwill & Intangibles over 5 years: stood at $94.7 billion in 2022, then surged by 40.04% to $132.7 billion in 2023, then slipped by 6.59% to $123.9 billion in 2024, then rose by 0.85% to $125.0 billion in 2025, then retreated by 0.82% to $124.0 billion in 2026.
• Per Business Quant, the three latest PFE Goodwill & Intangibles figures stand at $124.0 billion (Q1 2026), $125.0 billion (Q4 2025), and $120.4 billion (Q3 2025).

Peer Comparison